Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ausdauer who wrote (1458)	2/7/2003 4:46:45 PM
From: Biomaven	Read Replies (3) \| Respond to of 1477

Aus, benefits have been greatly overexagerated Certainly not by me. Nobody is claiming mortality benefits over nitroglycerin - indeed there is a (weak) argument that the trials showed it to be a little worse. However, it is clear that it is easier to use than existing drugs, and hospitals can likely save a little money by using it. Further, it almost certainly is safer than Milrinone and other inotropes, and works somewhat more quickly than nitro. So it's not a breakthrough drug, but it doesn't have to be given the large size of the market and the absence of any branded competition at all. If it works marginally better and costs marginally less to use (because less monitoring needed), then that's all you need to sell a lot of drug. Peter